240 related articles for article (PubMed ID: 32587297)
41. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
42. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network.
Gu X; Tohme R; Tomlinson B; Sakre N; Hasipek M; Durkin L; Schuerger C; Grabowski D; Zidan AM; Radivoyevitch T; Hong C; Carraway H; Hamilton B; Sobecks R; Patel B; Jha BK; Hsi ED; Maciejewski J; Saunthararajah Y
Leukemia; 2021 Apr; 35(4):1023-1036. PubMed ID: 32770088
[TBL] [Abstract][Full Text] [Related]
43. Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
Schwartsmann G; Fernandes MS; Schaan MD; Moschen M; Gerhardt LM; Di Leone L; Loitzembauer B; Kalakun L
Leukemia; 1997 Mar; 11 Suppl 1():S28-31. PubMed ID: 9130689
[TBL] [Abstract][Full Text] [Related]
44. Decitabine.
Daskalakis M; Blagitko-Dorfs N; Hackanson B
Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
[TBL] [Abstract][Full Text] [Related]
45. Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
Drugs R D; 2003; 4(3):179-84. PubMed ID: 12757405
[TBL] [Abstract][Full Text] [Related]
46. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia.
Lemaire M; Momparler LF; Bernstein ML; Marquez VE; Momparler RL
Anticancer Drugs; 2005 Mar; 16(3):301-8. PubMed ID: 15711182
[TBL] [Abstract][Full Text] [Related]
47. The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia.
Soncini M; Santoro F; Gutierrez A; Frigè G; Romanenghi M; Botrugno OA; Pallavicini I; Pelicci P; Di Croce L; Minucci S
Biochim Biophys Acta; 2013 Jan; 1832(1):114-20. PubMed ID: 23046813
[TBL] [Abstract][Full Text] [Related]
48. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.
Si J; Boumber YA; Shu J; Qin T; Ahmed S; He R; Jelinek J; Issa JP
Cancer Res; 2010 Sep; 70(17):6968-77. PubMed ID: 20713525
[TBL] [Abstract][Full Text] [Related]
49. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.
Pappalardi MB; Keenan K; Cockerill M; Kellner WA; Stowell A; Sherk C; Wong K; Pathuri S; Briand J; Steidel M; Chapman P; Groy A; Wiseman AK; McHugh CF; Campobasso N; Graves AP; Fairweather E; Werner T; Raoof A; Butlin RJ; Rueda L; Horton JR; Fosbenner DT; Zhang C; Handler JL; Muliaditan M; Mebrahtu M; Jaworski JP; McNulty DE; Burt C; Eberl HC; Taylor AN; Ho T; Merrihew S; Foley SW; Rutkowska A; Li M; Romeril SP; Goldberg K; Zhang X; Kershaw CS; Bantscheff M; Jurewicz AJ; Minthorn E; Grandi P; Patel M; Benowitz AB; Mohammad HP; Gilmartin AG; Prinjha RK; Ogilvie D; Carpenter C; Heerding D; Baylin SB; Jones PA; Cheng X; King BW; Luengo JI; Jordan AM; Waddell I; Kruger RG; McCabe MT
Nat Cancer; 2021 Oct; 2(10):1002-1017. PubMed ID: 34790902
[TBL] [Abstract][Full Text] [Related]
50. Decitabine activates specific caspases downstream of p73 in myeloid leukemia.
Tamm I; Wagner M; Schmelz K
Ann Hematol; 2005 Dec; 84 Suppl 1():47-53. PubMed ID: 16193303
[TBL] [Abstract][Full Text] [Related]
51. CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.
Allan JN; Roboz GJ; Askin G; Ritchie E; Scandura J; Christos P; Hassane DC; Guzman ML
Leuk Lymphoma; 2018 Apr; 59(4):821-828. PubMed ID: 28718760
[TBL] [Abstract][Full Text] [Related]
52. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.
Vasu S; He S; Cheney C; Gopalakrishnan B; Mani R; Lozanski G; Mo X; Groh V; Whitman SP; Konopitzky R; Kössl C; Bucci D; Lucas DM; Yu J; Caligiuri MA; Blum W; Adam PJ; Borges E; Rueter B; Heider KH; Marcucci G; Muthusamy N
Blood; 2016 Jun; 127(23):2879-89. PubMed ID: 27013443
[TBL] [Abstract][Full Text] [Related]
53. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
54. [Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].
Meng YS; Ma XX; Meng XQ; Wei R; Liu W; Ai GW; Zhang YX
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3406-10. PubMed ID: 18476539
[TBL] [Abstract][Full Text] [Related]
55. Hypomethylating agents and venetoclax in acute myeloid leukemia.
DiNardo CD
Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
[No Abstract] [Full Text] [Related]
56. DNA Methylation as a Therapeutic Target for Bladder Cancer.
Nunes SP; Henrique R; Jerónimo C; Paramio JM
Cells; 2020 Aug; 9(8):. PubMed ID: 32784599
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells.
Abou Najem S; Khawaja G; Hodroj MH; Babikian P; Rizk S
Cells; 2019 Nov; 8(12):. PubMed ID: 31766421
[TBL] [Abstract][Full Text] [Related]
58. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
59. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Daver N; Boddu P; Garcia-Manero G; Yadav SS; Sharma P; Allison J; Kantarjian H
Leukemia; 2018 May; 32(5):1094-1105. PubMed ID: 29487386
[TBL] [Abstract][Full Text] [Related]
60. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
Park H; Chung H; Lee J; Jang J; Kim Y; Kim SJ; Kim JS; Min YH; Cheong JW
Yonsei Med J; 2017 Jan; 58(1):35-42. PubMed ID: 27873493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
